机构地区:[1]温州医科大学附属第三医院心内科,浙江瑞安325200 [2]温州医科大学附属台州医院检验科,浙江台州318050
出 处:《中国医药导报》2013年第30期42-44,共3页China Medical Herald
基 金:浙江省医药卫生科技项目(编号2012ZHB022)
摘 要:目的探讨瑞舒伐他汀强化降脂对不稳定型心绞痛患者血清炎症因子的影响及疗效观察。方法选择不稳定型心绞痛患者76例,随机分为强化组及对照组,每组各38例。两组患者均予以常规治疗,强化组患者加用瑞舒伐他汀片20 mg/次,1次/d,对照组加用瑞舒伐他汀片10 mg/次,1次/d,两组疗程均为12周。观察两组患者治疗前后血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白介素-8(IL-8)的水平变化,并比较其临床疗效和药物不良反应发生率。结果治疗12周后,两组患者血清hs-CRP、TNF-α和IL-8水平较前明显下降(t=2.39、2.45、2.31、3.14、3.37、2.84,P<0.05),且强化组下降值明显大于对照组(t=2.38、2.44、2.24,P<0.05);同时强化组患者的临床总有效率(92.11%)明显高于对照组(73.68%)(χ2=4.55,P<0.05)。对照组和强化组治疗过程中分别出现药物不良反应4例(10.53%)和6例(15.79%),症状均较轻,两组比较差异无统计学意义(χ2=0.46,P>0.05)。结论瑞舒伐他汀强化降脂治疗不稳定型心绞痛具有较好的临床效果及安全性,能明显降低血清hs-CRP、TNF-α和IL-8等炎症因子水平,提高冠状动脉粥样斑块的稳定性,具有良好心血管保护作用。Objective To discuss the influence and curative effect of Rosuvastatin intensive lipid-lowering on serum inflam-mation cytokines of patients with unstable angina pectoris. Methods 76 cases of unstable angina pectoris patients were ran-domly divided into strengthened group and control group, with 38 cases in each group. The patients in two groups were given routine medical treatment, the patients in strengthened group were given 20 mg Rosuvastatin one time and once a day for 12 weeks, while the patients in control group were given 10 mg Rosuvastatin one time and once a day for 12 weeks additionally. The changes of serum hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor (TNF-α and interleukin-8 (IL-8) levels of patients in two groups were observed before and after medical treatment, and the clinical curative effect and the oc-currence rates of drug adverse reaction (DAR) were compared as well. Results After 12 weeks' medical treatment, the levels of serum hs-CRP, TNF-α and IL-8 of patients in two groups declined obviously than before (t = 2.39, 2.45, 2.31, 3.14, 3.37, 2.84, P 〈 0.05), and the declining rate in strengthened group was much higher than that in control group (t = 2.38, 2.44, 2.24, P 〈 0.05). Meanwhile, the total clinical efficiency of patients in strengthened group (92.11%) was much higher than that in control group (73.68%) (X^2 = 4.55, P 〈 0.05). 4 cases (10.53%) and 6 cases (15.79%) of DAR with light symptom were appeared in control group and strengthened group during the medical treatment, there was no statistical difference between the two groups (X^2 = 0.46, P 〉 0.05). Conclusion Rosuvastatin intensive lipid-lowering has rehable curative effect and security for patients with unstable angina pectoris, which can reduce obviously the inflammation cytokines levels such as serum hs-CRP, TNF-α, IL-g and etc, improve the coronary atherosclerotic plaque stability, and has a good role in the cardiovascular protec-tion.
关 键 词:不稳定型心绞痛 瑞舒伐他汀 超敏C反应蛋白 肿瘤坏死因子-α 白介素-8
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...